These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38948068)

  • 41. Metronomic therapy in the treatment of cancer.
    Mazánková D; Bárková V; Mazánek P
    Ceska Slov Farm; 2022; 71(3):91-97. PubMed ID: 36058637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice.
    Tagliamonte M; Petrizzo A; Napolitano M; Luciano A; Rea D; Barbieri A; Arra C; Maiolino P; Tornesello M; Ciliberto G; Buonaguro FM; Buonaguro L
    J Transl Med; 2016 Feb; 14():58. PubMed ID: 26911136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer.
    Gille J; Spieth K; Kaufmann R
    J Dtsch Dermatol Ges; 2005 Jan; 3(1):26-32. PubMed ID: 16353746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metronomic scheduling: the future of chemotherapy?
    Gasparini G
    Lancet Oncol; 2001 Dec; 2(12):733-40. PubMed ID: 11902515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metronomic chemotherapy.
    Mutsaers AJ
    Top Companion Anim Med; 2009 Aug; 24(3):137-43. PubMed ID: 19732732
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Close A
    Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.
    Benzekry S; Hahnfeldt P
    J Theor Biol; 2013 Oct; 335():235-44. PubMed ID: 23850479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of VEGF and other parameters in tracking the clinical course in metronomic chemotherapy.
    Ekinci D; Kargi A; Yalcin AD; Savas B
    J BUON; 2013; 18(1):245-52. PubMed ID: 23613412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.
    Lambrescu I; Fica S; Martins D; Spada F; Cella C; Bertani E; Rubino M; Gibelli B; Grana C; Bonomo G; Funicelli L; Ravizza D; Pisa E; Zerini D; Ungaro A; Fazio N;
    Cancer Treat Rev; 2017 Apr; 55():46-56. PubMed ID: 28314176
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metronomic therapy concepts in the management of adrenocortical carcinoma.
    Berruti A; Sperone P; Bellini E; Daffara F; Perotti P; Ardito A; Saini A; Terzolo M
    Horm Cancer; 2011 Dec; 2(6):378-84. PubMed ID: 21971765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel.
    Luan X; Guan YY; Lovell JF; Zhao M; Lu Q; Liu YR; Liu HJ; Gao YG; Dong X; Yang SC; Zheng L; Sun P; Fang C; Chen HZ
    Biomaterials; 2016 Jul; 95():60-73. PubMed ID: 27130953
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology.
    Marconato L; Chalfon C; Finotello R; Polton G; Vasconi ME; Annoni M; Stefanello D; Mesto P; Capitani O; Agnoli C; Amati M; Sabattini S
    Vet Comp Oncol; 2019 Dec; 17(4):537-544. PubMed ID: 31251441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-dose metronomic chemotherapy: a systematic literature analysis.
    Lien K; Georgsdottir S; Sivanathan L; Chan K; Emmenegger U
    Eur J Cancer; 2013 Nov; 49(16):3387-95. PubMed ID: 23880474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metronomic chemotherapy: A relook at its basis and rationale.
    Rajasekaran T; Ng QS; Tan DS; Lim WT; Ang MK; Toh CK; Chowbay B; Kanesvaran R; Tan EH
    Cancer Lett; 2017 Mar; 388():328-333. PubMed ID: 28003122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.
    Shaked Y; Emmenegger U; Man S; Cervi D; Bertolini F; Ben-David Y; Kerbel RS
    Blood; 2005 Nov; 106(9):3058-61. PubMed ID: 15998832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules.
    Banchi M; Cox MC; Bocci G
    Cancer Lett; 2024 Jun; 591():216900. PubMed ID: 38636896
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
    Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
    Zapletalova D; André N; Deak L; Kyr M; Bajciova V; Mudry P; Dubska L; Demlova R; Pavelka Z; Zitterbart K; Skotakova J; Husek K; Martincekova A; Mazanek P; Kepak T; Doubek M; Kutnikova L; Valik D; Sterba J
    Oncology; 2012; 82(5):249-60. PubMed ID: 22538363
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamics and control of a mathematical model for metronomic chemotherapy.
    Ledzewicz U; Amini B; Schättler H
    Math Biosci Eng; 2015 Dec; 12(6):1257-75. PubMed ID: 26775862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of metronomic chemotherapy in oncology: results from a national Italian survey.
    Collovà E; Sebastiani F; De Matteis E; Generali D; Aurilio G; Boccardo F; Crispino S; Cruciani G
    Tumori; 2011; 97(4):454-8. PubMed ID: 21989433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.